small molecule

EDLUAR

ZOLPIDEM TARTRATE

Loss of exclusivityFebruary 2031latest FDA-listed patent expiry
CompanyVIATRIS SPECIALTY LLC

Drug detail

Brand nameEDLUAR
Active ingredientZOLPIDEM TARTRATE
Strength5MG
Dosage formTABLET
RouteSUBLINGUAL
ModalitySmall molecule
FDA approvalMarch 2009
Marketing statusRX

Listed patents

PatentExpiresType
9265720February 2031use U-674
9597281April 2027use U-674

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

EDLUAR patent cliff — loss of exclusivity February 2031 | CliffBio